Guiding Vaccine Development with Machine Learning
Pacific Northwest National LaboratoryThe Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.
The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.
Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system response. If validated in clinical trials, the technology could help scientists overcome a major hurdle to developing personalized immunotherapies and vaccines.
Cedars-Sinai and BlackDoctor.org will host a virtual community conversation to help kick-off the back-to-school season.
University of Adelaide researchers have started work on developing a new vaccine that could help ward off painful ear infections in children. The potential vaccine is in the initial stages of development in the lab and will target one of the main types of bacteria that cause middle ear infections, a common illness among infants and young children.
A collaborative research effort led by the University of Michigan and the Icahn School of Medicine at Mount Sinai has resulted in a nasal vaccine adjuvant that stops COVID infection in both young and old mice.
At the beginning of the mass vaccination against COVID-19 infection, the government had to determine eligibility for priority vaccination.
Which types of personalities were more hesitant about COVID-19 vaccination during the pandemic’s peak? Extroverts — according to a new study on more than 40,000 Canadians.
Even vulnerable people, who are at risk of severe Covid-19, achieved good antibody levels after three doses of mRNA vaccine.
The coronavirus pandemic is no longer a national emergency, but the virus that causes COVID-19 isn’t gone—and neither is the risk of getting the disease. For parents, navigating when to get their child vaccinated and knowing how to best protect their child from COVID-19 can be complicated. We spoke to Michael Smit, MD, MSPH, Hospital Epidemiologist and Medical Director of Infection Prevention and Control at Children’s Hospital Los Angeles, to get an update on the latest COVID-19 vaccine information and precautions.
Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies.
In a new study, scientists at La Jolla Institute for Immunology (LJI) compared the immune response of individuals who received older versus newer versions of the whooping cough vaccine. The unexpected findings may help explain the recent rise in whooping cough cases and point to potential targets for the next generation of vaccines.
Cancer patients saw a significant fall in Covid-related hospitalisations and mortality following the rollout of vaccines in the first panoramic study of its kind.
Immune system researchers have designed a computational tool to boost pandemic preparedness. Scientists can use this new algorithm to compare data from vastly different experiments and better predict how individuals may respond to disease.
A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.
An analysis of real-world data from more than 1.2 million patients from health systems in four geographically dispersed states -- Indiana, Oregon, Texas and Utah -- conducted by the U.S. Centers for Disease Control and Prevention’s VISION Network, has determined both the number of adults needed to be vaccinated to prevent one COVID-19 associated hospitalization and the number needed to be vaccinated to prevent one COVID-19 associated emergency department (ED) visit.
When people who publicly reject COVID-19 vaccines later die from the disease, observers have complex reactions to their fates, a new study suggests. While very few rejoice in the deaths of anti-vaxxers, some people believe those who are dogmatic against vaccines are deserving of worse outcomes – and that reaction is related to the political party affiliation and vaccination status of the person evaluating the anti-vaxxer.
The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
A vaccine candidate that can protect children from Meningococcal group B (MenB), which can lead to meningitis, has progressed to clinical development, according to an announcement by researchers from the University of Surrey and the University of Oxford.
CEPI to provide up to $4.98 USD million to Houston Methodist Research Institute-led consortium to use artificial intelligence for design of vaccines to fight diseases with pandemic potential. The project will support a consortium, led by HMRI, to design potential antigenic targets for up to 10 priority virus families with epidemic or pandemic potential. Laboratory-based tests will then be used to verify antigen designs for possible further development.
BU research highlights how healthcare inequities between urban and rural areas, and vaccine skepticism, played a role in deaths related to COVID.
Giving patients with operable pancreatic cancers a three-pronged combination immunotherapy treatment consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment, is safe, it increases the amount of cancer-killing immune system T cells in the tumors and it appears effective when given two weeks prior to cancer-removal surgery, according to new research directed by Johns Hopkins investigators.
Human papillomavirus (HPV) is a ubiquitous virus, and most people are infected at some point in their lives. HPV can infect epithelial cells of the skin and mucosa at various sites.
A new study conducted by researchers at Bar-Ilan University in Israel has shed light on the long-term impact of COVID-19 on the quality of life among different ethnic groups in the country. The study, part of a larger cohort project, highlights a significant discrepancy between Arabs and Druze, and Jews, with the two former groups experiencing a more pronounced decline in quality of life one year after infection.
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.
A UCLA-led team has received $925,000 as part of a new grant from the Centers for Disease Control and Prevention (CDC) to conduct four surveillance projects tracking outbreaks of mpox--formerly known as monkeypox—across the U.S.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for June 2023.
COVID-19 vaccination helped reduce disparities in disease incidence between low- and high-income communities, according to a new analysis led by Cedars-Sinai investigators.
Johns Hopkins Medicine scientists say they have developed a nanoparticle — an extremely tiny biodegradable container — that has the potential to improve the delivery of messenger ribonucleic acid (mRNA)-based vaccines for infectious diseases such as COVID-19, and vaccines for treating non-infectious diseases including cancer.
A new study by researchers in the UNC School of Medicine, including Meghan Rebuli, PhD, Ilona Jaspers, PhD, and Kevin T. Cao, lead author, has found that SARS-CoV-2 mRNA vaccination induces an immune response in the mucosal lining of the nasal cavity, offering new insights into potential vaccine strategies in the future.
A 2022 outbreak of mpox (formerly monkeypox) sickened more than 30,000 people and caused 38 deaths in the United States. It highlighted the lack of an approved vaccine for those under 18 years old.
A team of researchers from the Chinese Academy of Sciences, the Chinese Academy of Agricultural Sciences, and Beijing Institute of Pharmacology and Toxicology have made significant progress in developing multi-valent mRNA vaccines against monkeypox virus (MPV), the agent that can cause smallpox-like disease in humans.
A new study from researchers at the University of Wisconsin–Madison offers a first-of-its-kind visual of a non-mammal species' adaptive immune system in action. The advance holds potential implications for a range of scientific aims, from improving wildlife vaccines to better understanding fundamental disease processes and possibly the evolution of adaptive immunity itself.
Researchers from Children’s Hospital of Philadelphia (CHOP) have engineered stable, universal MHC-I molecules that can be produced rapidly at scale, allowing researchers not only to develop vaccines and immunotherapies more quickly but also to identify molecules that can work broadly across the population. The findings were published today in the Proceedings of the National Academy of Sciences.
A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children (most of them age 4 and younger) found no indications of serious side effects.
New Olin Business School research demonstrates the effectiveness of partisan cues in a COVID-19 vaccination video ad campaign.A large-scale study to see if politically partisan cues can induce people to get COVID-19 vaccines found that, yes, they can.
A successful long-term experiment with live hogs indicates Nebraska scientists may be another step closer to achieving a safe, long-lasting and potentially universal vaccine against swine flu.
Scientists at La Jolla Institute for Immunology show that T cells can recognize several different viral targets, called "antigens," shared between most coronaviruses, including common cold coronaviruses and SARS-CoV-2. They also looked more in-depth at what fragments of these antigens, called “epitopes,” are recognized and how conserved they are across different coronaviruses.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the American Society for Clinical Oncology’s annual meeting, June 2-6 in Chicago, Illinois, see our list of Fred Hutch research highlights at ASCO and contact [email protected] to set up interviews with experts.
Scientists have spent years trying to develop an effective HIV vaccine, but none have proven successful. Based on findings from a recently published study, a Johns Hopkins Medicine-led research team may have put science one step closer to that goal.
Cytomegalovirus (CMV) is one of the most prevalent herpesviruses worldwide. Depending on the geographical area, it can affect between 40% and 90% of the population and, although it does not produce symptoms in healthy people, the control of this chronic infection requires constant work by the immune system, which is constantly fighting to keep it at bay.
A San Diego team, led by scientists at La Jolla Institute for Immunology (LJI), has won the top prizes in the Nucleate Activator competition. Out of 1,000 initial competitors, the LJI team advanced to the final four teams and swept all the prizes they entered for. Their winning research proposal outlines how scientists could stop dengue virus and Zika virus by developing sophisticated vaccines that activate both B cells and T cells.
A new study published in JCI Insight, led by Angela Wahl, PhD, Raymond Pickles, PhD, and J. Victor Garcia, PhD, with the International Center for the Advancement of Translational Science (ICATS), the Department of Microbiology and Immunology, and the Institute for Global Health and Infectious Diseases (IGHID) at the UNC School of Medicine has shown that human T cells have an important role to play in controlling infection.
University of Delaware researchers in the lab of Aditya Kunjapur, assistant professor in the College of Engineering’s Department of Chemical and Biomolecular Engineering, have engineered bacteria to synthesize an amino acid that contains a rare functional group that others have shown to have implications in the regulation of our immune system. The researchers also taught a single bacterial strain to create the amino acid and place it at specific sites within target proteins.
During last year’s mpox outbreak, the virus spread for the first time outside Africa, causing over 85,000 cases of the disease to date. Men who have sex with men account for the most infections, with a marked skew towards the young.
Previous studies have shown that the mortality rate of Corona patients hospitalized and requiring oxygen therapy is similar no matter if they are vaccinated or unvaccinated. An international research team led by David Gómez-Varela from the Department for Pharmaceutical Sciences at the University of Vienna has now disproved these findings in a comprehensive multicontinental analysis published in the high-impact Journal of Medical Virology: The number of deaths of hospitalized patients would have been 22% lower if all unvaccinated, oxygen-dependent individuals had been vaccinated.